Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
Blair HA. Blair HA. Drugs. 2019 Feb;79(3):303-313. doi: 10.1007/s40265-019-1056-1. Drugs. 2019. PMID: 30689194 Review.
Tolvaptan [Jynarque() (USA); Jinarc() (EU, Canada); Samsca() (Japan)] is a highly selective vasopressin V(2) receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). ...
Tolvaptan [Jynarque() (USA); Jinarc() (EU, Canada); Samsca() (Japan)] is a highly selective vasopressin V(2) receptor antagonist appr …
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
Blair HA, Keating GM. Blair HA, et al. Drugs. 2015 Oct;75(15):1797-806. doi: 10.1007/s40265-015-0475-x. Drugs. 2015. PMID: 26407729 Review.
Tolvaptan (Jinarc()) is a highly selective vasopressin V2 receptor antagonist indicated for use in patients with autosomal dominant polycystic kidney disease (ADPKD). ...
Tolvaptan (Jinarc()) is a highly selective vasopressin V2 receptor antagonist indicated for use in patients with autosomal dominant p …
TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
Olalekan K, Fox A, Gilbert R. Olalekan K, et al. Arch Dis Child. 2016 Sep;101(9):e2. doi: 10.1136/archdischild-2016-311535.61. Arch Dis Child. 2016. PMID: 27540244
BACKGROUND: Unlicensed medications are used all the time in the management of diseases in childhood. Tolvaptan (Jinarc) is a vasopressin V2-receptor antagonist licensed for use to slow the progression of cyst development and renal insufficiency of ADPKD in adults with CKD …
BACKGROUND: Unlicensed medications are used all the time in the management of diseases in childhood. Tolvaptan (Jinarc) is a vasopres …